CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute myeloid leukemia, myelodysplastic syndromes and myelofibrosis.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with acute myeloid leukemia, myelodysplastic syndromes and myelofibrosis.
  
  LEARNING OBJECTIVES

  • Analyze how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with myelofibrosis (MF), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  • Appreciate published clinical trial results documenting the effectiveness of approved and investigational JAK inhibitors in MF, and identify patients for whom treatment with each of these agents would be appropriate.
  • Recognize the FDA approval of venetoclax in combination with a hypomethylating agent or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and discern how these regimens can be optimally integrated into nonresearch care algorithms.
  • Develop an understanding of the available data with and current roles of IDH1 and IDH2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and a relevant genetic abnormality.
  • Consider Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and discern how this novel strategy can be appropriately applied in clinical care.
  • Describe the biological rationale for and mechanism of action of luspatercept in the treatment of anemia secondary to MDS or MF, and recognize how this agent can be appropriately integrated into clinical practice.
  • Recollect the side effects and toxicities associated with commonly employed agents for MF, AML and MDS, and use this information to develop supportive care plans for patients undergoing treatment with these therapies.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ilene Galinsky, NP
  Senior Adult Leukemia Program Research Nurse Practitioner
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, Novartis.
  
  Ruben A Mesa, MD
  President, Enterprise Cancer Service Line
  Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
  Enterprise Senior Vice President, Atrium Health
  Vice Dean for Cancer Programs
  Professor of Medicine
  Wake Forest University School of Medicine
  Winston-Salem, North Carolina
  
  Advisory Committee: AbbVie Inc, Geron, Incyte Corporation, Telios Pharma Inc; Consulting Agreements: Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma Corp, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, MorphoSys, Novartis, Protagonist Therapeutics, Sierra Oncology; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma Corp, Incyte Corporation, Sierra Oncology; Data and Safety Monitoring Board/Committee: Geron, Telios Pharma Inc.
  
  Daniel A Pollyea, MD, MS
  Professor of Medicine
  Clinical Director of Leukemia Services
  Associate Chief of Clinical Affairs
  Robert H Allen, MD Chair in Hematology Research
  Division of Hematology
  University of Colorado School of Medicine
  Aurora, Colorado
  
  Advisory Committee: AbbVie Inc, Adicet Bio, Arcellx, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, BerGenBio ASA, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, HiberCell, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Link Pharma, Magenta Therapeutics, Medivir AB, Novartis, OncoVerity, Qihan Biotech, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Seres Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Zentalis Pharmaceuticals; Consulting Agreements: AbbVie Inc, Aptevo Therapeutics, Schrödinger, Syros Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Karyopharm Therapeutics, Teva Oncology; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, GlycoMimetics Inc.
  
  Richard M Stone, MD
  Lunder Family Chair in Leukemia
  Chief of Staff
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Board: AbbVie Inc, Actinium Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, AvenCell, Boston Pharmaceuticals, Bristol Myers Squibb, Celularity, CTI BioPharma Corp, Genentech, a member of the Roche Group, GSK, Hemavant, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Lava Therapeutics, Ligand Pharmaceuticals Incorporated, Novartis, Syros Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; AML Expert Council: GSK; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, Epizyme Inc,Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Focus Group: BerGenBio ASA; Grand Rounds: Jazz Pharmaceuticals Inc; Steering Committee: AbbVie Inc.
  
  Sara M Tinsley-Vance, PhD, APRN, AOCN
  Nurse Practitioner and Researcher
  Malignant Hematology
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committee: Bristol Myers Squibb, CTI BioPharma Corp, Incyte Corporation, Jazz Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, Incyte Corporation; Speakers Bureau: Astellas, Bristol Myers Squibb, CTI BioPharma Corp, Incyte Corporation, Jazz Pharmaceuticals Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp, and GSK.
  
  Release date: June 2023
  Expiration date: June 2024
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.